Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| (NASDAQ: LNTH) | Delayed: 100.31 -0.15 (0.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $100.46 | 52 Week High | $10.70 | |||
| Open | $100.50 | 52 Week Low | $1.76 | |||
| Day High | $100.59 | P/E | N/A | |||
| Day Low | $100.31 | EPS | $0.00 | |||
| Volume | 931,763 | |||||
